Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
Jinzi WU
Jinzi WU
Positions:

Founder, Chairman & CEO

Company:

Ascletis Pharma Inc.

Dr. Jinzi J. Wu is Founder, Chairman and CEO of Ascletis which was founded in April 2013. Ascletis is an innovative R&D driven biotech with two commercial products. Led by Dr. Wu, Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in August 2018 and raised US$400M. Under his leadership, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Led by Dr. Wu, Ganovo® (Danoprevir), Ascletis’ first direct-acting antiviral agent (DAA) for hepatitis C, was successfully launched in June 2018 and is now commercialized by Ascletis’ 180+ member commercial team. Dr. Wu and his team filed NDA in August 2018 for Ravidasvir, Ascletis’ second DAA for hepatitis C with best-in-class characteristics. Under his leadership, Ascletis has built an innovative R&D pipeline focusing on viral, cancer and fatty liver diseases and consisting of antibody-based immunotherapy, first/best-in-class small molecules and siRNA at various clinical development stages.

 

Dr. Wu has more than 20-year experience covering R&D, GMP manufacturing and commercialization in Big Pharma and biotech. Prior to founding Ascletis, he was Vice President at GSK R&D in USA. He also held various R&D positions from Sr. Scientist to Vice President at Novartis, Immunex/Amgen and Ambrilia in USA and Canada. Dr Wu obtained his PhD in Cancer Biology from University of Arizona.